Evidence map›Paper›PMID 36918834›Full record

ArticleBMC cancer2023

Effect of neoadjuvant chemotherapy combined with arterial chemoembolization on short-term clinical outcome of locally advanced gastric cancer.

Jianguo Yang, Juncai Li, Qican Deng, Zhenzhou Chen, Kuan He, Yajun Chen, Zhongxue Fu

RetractedOpen access · goldFull text readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Jianguo YangDepartment of Gastrointestinal surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Juncai LiDepartment of Thoracic Surgery, Yubei District people's Hospital of Chongqing, Chongqing, China.
Qican DengDepartment of Gastrointestinal surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Zhenzhou ChenDepartment of Gastrointestinal surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Kuan HeDepartment of Gastrointestinal surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Yajun ChenDepartment of Gastrointestinal surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Zhongxue FuDepartment of Gastrointestinal surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. fzx19990521@126.com.
The Affiliated Yongchuan Hospital of Chongqing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe purpose of this study was to explore the short-term efficacy and safety of neoadjuvant chemotherapy combined with arterial chemoembolization for locally advanced gastric cancer (LAGC).

methodsWe retrospectively analyzed the clinical data of 203 patients with LAGC who received neoadjuvant therapy from June 2019 to December 2021. The patients were divided into a neoadjuvant chemotherapy combined with arterial chemoembolization group (combined group, n = 102) and a neoadjuvant chemotherapy group (conventional group, n = 101). The adverse events of chemotherapy, postoperative complications and pathological complete response (pCR) rate were compared between the two groups. Univariate and multivariate analyses were performed to evaluate the potential factors affecting pCR.

resultsA total of 78.8% of the patients were in clinical stage III before neoadjuvant therapy. A total of 52.2% of the patients underwent surgery after receiving two cycles of neoadjuvant therapy. There were 21.2% patients with ≥ grade 3 (CTCAE 4.0) adverse events of chemotherapy and 11.3% patients with Clavien-Dindo classification ≥ grade 3 postoperative complications. Compared with the conventional group, the combination group did not experience an increase in the adverse events of chemotherapy or postoperative complications. The pCR rate in the combined group was significantly higher than that in the conventional group (16.7% vs. 4.95%, P = 0.012). The multivariate analysis showed that arterial chemoembolization, pre-treatment neutrophil-to-lymphocyte ratio (NLR) and pre-treatment platelet-to-lymphocyte ratio (PLR) were independent factors affecting pCR.

conclusionNeoadjuvant chemotherapy combined with arterial chemoembolization contributed to improving the pCR rate of LAGC patients. Arterial chemoembolization, pre-treatment NLR and pre-treatment PLR were also predictors of pCR.

Indexed as

Neoadjuvant TherapyStomach NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansLymphocytesPostoperative ComplicationsRetrospective StudiesAdverse eventsArterial chemoembolizationGastric cancerNeoadjuvant therapyPathological complete responsePostoperative complications

Identifiers

PMID36918834
PMCPMC10015836
OpenAlexW4324193875

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read344
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.